Alligator Bioscience 2025 Investor Presentation

Alligator Bioscience is a Phase 3-ready biotech company developing innovative antibody-based immunotherapies for cancer. The presentation highlights mitazalimab, their lead candidate for metastatic pancreatic cancer, which demonstrated significant survival benefits in Phase 2 trials as a combination therapy, with regulatory confirmation of the path to approval. The company is also advancing ATOR-4066, a first-in-class CD40 bispecific antibody follow-on candidate.